-
SAMU SummariesNo resources currently available.
-
Guidelines
-
MSF TB Guideline (2014)
-
WHO: Guideline on DRTB (2016)
-
WHO: Companion Handbook to the Guidelines on the Management of DRTBRead more
WHO: Companion Handbook to the Guidelines on the Management of DRTB -
WHO: The use of delamanid in the treatment of multidrug-resistant tuberculosisRead more
WHO: The use of delamanid in the treatment of multidrug- resistant tuberculosis -
WHO: The use of bedaquiline in the treatment of multidrug-resistant tuberculosisRead more
WHO: The use of bedaquiline in the treatment of multidrug-resistant tuberculosis -
endTB Guidelines on the Use of New Drugs in the Management of DRTBRead more
endTB Guidelines on the Use of New Drugs in the Management of DRTB -
MSF HIV/TB Clinical Guide for Primary Care 2018Read more
MSF HIV/TB Clinical Guide for Primary Care
Manuel clinique MSF VIHTB pour les soins de santé primaires -
WHO Consolidated Guidelines on DR-TB Treatment (2019)
-
-
Implementation Resources
-
MSF TB Patient Education and Counselling Flipchart: DS-TB, MDR-TB & XDR-TB MessagesRead more
TB Patient Education and Counselling Flipchart: DS-TB, MDR-TB & XDR-TB Messages -
Counselling toolkit for DRTB (Khayelitsha)
-
WHO: Policy Implementation package for new TB drug introduction (2014)Read more
WHO: Policy Implementation package for new TB drug introduction
-
-
Training ResourcesNo resources currently available.
-
Want to Know More
-
Out of Step: TB policies in 29 countries (2017)
-
Self-administered therapy for DRTB treatment: Experience from MSF Khayelitsha, South AfricaRead more
Self-administered therapy for DRTB treatment: Experience from MSF Khayelitsha, South Africa -
Decentralisation of DRTB treatment: Experience from MSF in SwazilandRead more
Decentralisation of DRTB treatment: Experience from MSF in Swaziland -
endTB Interim Analysis: July 2018
-
MSF DRTB abstracts from the UNION conference 2017Read more
Delamanid for rifampicin resistant tuberculosis an observational cohort study from Khayelitsha
Adverse events over 6 months with delamanid in a programmatic setting in Khayelitsha
Accelerating access to delamanid for rifampicin-resistant tuberculosis in Khayelitsha, South Africa
Early safety and efficacy of Bedaquiline and Delamanid combination for drug-resistant TB in Armenia, India and South Africa
-
-
UpdatesNo resources currently available.
-
Additional ResourcesNo resources currently available.